Someone's Betting On Dendreon Corporation (DNDN)
4/10/2007 2:48:12 AM
Investors are betting that the U.S. Food and Drug Administration will break with tradition and approve Dendreon's prostate cancer treatment. The company's stock, which traded below $4 in March, soared 30.6% on Monday, to $23.58, a $5.53 gain.
>>> Discuss This Story